Diligence memo · auto-generated · as of July 2, 2026
Intu Diagnostics
Intu Diagnostics looks fair against its niche peers and is active on financing cadence.
Businessfiled
Intu Diagnostics operates in Medical Devices, based in Europe. <p>Intu Diagnostics, a Liepzig-based startup developing a platform for completely lab-free molecular diagnostics, has closed a €1.1 million strategic bridge round- bringing their total funding secured to over €3 million. The round was supported by BSV Ventures, SAB (Saxonian Development Bank) and bu
Sub-sector tags: medical-devices.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Intu Diagnostics has raised $1.2M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.2M on 2026-06-26.
Most recent recorded round closed around 2026-06-26.
Valuation (modeled)modeled
Provath models Intu Diagnostics at approximately $2.2M (range $962K–$3.4M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.22× the median modeled value of Seed Medical Devices companies in 2025–2027 (8 peers) — value vs value, same stage and era. Within the normal band (122% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise under a month ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 45% of Medical Devices peers (233 compared).
Modeled value ranks above 25% of those peers.
Closest niche peers: Rose Diagnostics Inc., Pace Surgical, Inc., MemorialCare Surgical Center at Saddleback, LLC, Persperion Diagnostics Inc., Origami Surgical Inc..
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.